Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Wellinks Closed $10 Million Series B Funding from UMass Memorial Health and Inside Investors
Investment Builds on Wellinks’ Strategic Partnership with UMass Memorial Health and Other Commercial Partners to Accelerate Growth and Expand Patient Access to Its Predictive Care Model
Wellinks, a leader in cardiopulmonary care, today announced the first close of its Series B Funding, securing $10 million to fund commercial growth with participation from UMass Memorial Health and inside investors. The investment builds on Wellinks’ multiyear relationship with UMass Memorial Health and other partners to accelerate the expansion of Wellinks’ predictive care solution.
Wellinks’ FDA-cleared Spire Remote Patient Monitoring (RPM) System helps identify early physiologic changes associated with clinical deterioration, supporting earlier intervention and proactive management of chronic respiratory disease beyond traditional care settings.
Wellinks and UMass Chan Medical School first collaboratively approached reducing acute care utilization in COPD patients through the Healthy at Home program. The study found that Healthy at Home participants had more than 60% lower odds of 30-day hospital readmission, with trends toward fewer emergency department visits and shorter hospital stays than similar patients who did not participate. For more information, read “Healthy at Home study demonstrates feasibility, effectiveness of mobile care for COPD.”
“Our continued collaboration with Wellinks reflects a shared commitment to advancing proactive, data-driven care,” said Dr. Eric Dickson, CEO at UMass Memorial Health. “Together, we’re generating real-world clinical evidence that supports better outcomes for patients and informs the future of cardiopulmonary care.”
Wellinks will use the funding to…
Full release here, originally announced August 4th, 2026.
Function Secures $450 Million Growth Financing from General Catalyst’s Customer Value Fund (CVF)
Financing Will Accelerate Function’s Mission to Help Millions More People Own Their Health
Function today announced the closing of $450 million in growth financing from General Catalyst’s Customer Value Fund, accelerating the company’s mission to help millions more people understand and take ownership of their health.
The financing underscores conviction in Function’s vision to fundamentally change how people take ownership of their health. Since early beta launch in 2023, Function has defined a new category by bringing lab testing, imaging, and personalized intelligence into a single platform designed for lifelong health.
The capital will enable Function to bring its platform to millions more people faster. This announcement comes on the heels of Function’s Q2 expansion acquisitions of Getlabs’ nationwide at-home or office blood draw network and SuppCo’s supplement platform.
“Our mission is simple: enable you to live 100 healthy years. Everyone deserves to feel their best and avoid suffering,” said Jonathan Swerdlin, Co-Founder and CEO at Function. “Every dollar invested in Function is a vote for one hundred healthy years for eight billion people. This growth financing allows us to pull the inevitable and optimistic future of health into the present.”
“This financing reflects our belief that Function is one of the defining companies of our generation,” said Pranav Singhvi, Partner and Co-Head at CVF, General Catalyst…
Full release here, originally announced July 30th, 2026.
No comments:
Post a Comment